Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

被引：0
|
作者：
Laura C. Coates
Proton Rahman
Philip J. Mease
May Shawi
Emmanouil Rampakakis
Alexa P. Kollmeier
Xie L. Xu
Soumya D. Chakravarty
Iain B. McInnes
Lai-Shan Tam
机构：
[1] University of Oxford,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
[2] Memorial University of Newfoundland,Craig L Dobbin Genetics Research Centre, St. John’s, Newfoundland and Labrador
[3] University of Washington,Department of Rheumatology Research, Swedish Medical Center/Providence St Joseph Health
[4] Janssen Research & Development,Department of Pediatrics
[5] LLC,Division of Rheumatology
[6] McGill University,College of Medical Veterinary and Life Sciences
[7] JSS Medical Research,Department of Medicine & Therapeutics
[8] Inc,undefined
[9] Scientific Affairs,undefined
[10] Janssen Research & Development,undefined
[11] LLC. Immunology,undefined
[12] Janssen Scientific Affairs,undefined
[13] LLC,undefined
[14] Drexel University College of Medicine,undefined
[15] University of Glasgow,undefined
[16] The Chinese University of Hong Kong,undefined
来源：
BMC Rheumatology | / 8卷
关键词：
Psoriatic arthritis; Biologics; Guselkumab; Minimal disease activity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
    Coates, Laura C.
    Rahman, Proton
    Mease, Philip J.
    Shawi, May
    Rampakakis, Emmanouil
    Kollmeier, Alexa P.
    Xu, Xie L.
    Chakravarty, Soumya D.
    McInnes, Iain B.
    Tam, Lai-Shan
    [J]. BMC RHEUMATOLOGY, 2024, 8 (01)
  • [2] Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
    Coates, Laura C.
    Gossec, Laure
    Zimmermann, Miriam
    Shawi, May
    Rampakakis, Emmanouil
    Shiff, Natalie J.
    Kollmeier, Alexa P.
    Xu, Xie L.
    Nash, Peter
    Mease, Philip J.
    Helliwell, Philip S.
    [J]. RMD OPEN, 2024, 10 (01):
  • [3] Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Felten, Renaud
    Widawski, Laura
    Spielman, Lionel
    Gottenberg, Jacques-Eric
    Duret, Pierre-Marie
    Rampakakis, Emmanouil
    Sharaf, Mohamed
    Constantin, Caren
    Campana, Vincenza
    Messer, Laurent
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4429 - 4432
  • [4] Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Kavanaugh, Arthur
    Lam, Gordon
    Tam, Lin-Shan
    Shiff, Natalie
    Lee, Youngja
    Perdomo, Ana-Maria Bravo
    Shawi, May
    Hsia, Elizabeth
    Rampakakis, Emmanouil
    Gutierrez, Carlos Enrique Toro
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4170 - 4172
  • [5] LONG-TERM IMPROVEMENT IN INDIVIDUAL ACR RESPONSE CRITERIA AND RESIDUAL DISEASE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST HOC ANALYSIS OF A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY
    Nash, P.
    Mcinnes, I.
    Shawi, M.
    Nantel, F.
    Kollmeier, A.
    Rampakakis, E.
    Soriano, E.
    Gladman, D. D.
    Deodhar, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1769 - 1770
  • [6] SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
    Nielsen, S. Holm
    Bay-Jensen, A. C.
    Frederiksen, P.
    Karsdal, M.
    Shawi, M.
    Chakravarty, S. D.
    Kollmeier, A.
    Chen, W.
    Gao, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 342 - 343
  • [7] Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
    Nielsen, Signe Holm
    Bay-Jensen, Anne-Christine
    Frederiksen, Peder
    Karsdal, Morten
    Shawi, May
    Chakravarty, Soumya
    Kollmeier, Alexa
    Chen, Warner
    Gao, Sheng
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4219 - 4220
  • [8] Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab
    Nash, Peter
    McInnes, Iain
    Ritchlin, Christopher T.
    Tam, Lai-Shan
    Soriano, Enrique
    Starr, Michael
    Rampakakis, Emmanouil
    Lavie, Frederic
    Shawi, May
    Baraliakos, Xenofon
    Mease, Philip J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2785 - 2787
  • [9] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Ritchlin, Christopher
    Mease, Philip J.
    Boehncke, Wolf-Henning
    Tesser, John
    Chakravarty, Soumya
    Rampakakis, Emmanouil
    Shawi, May
    Schiopu, Elena
    Merola, Joseph
    McInnes, Iain B.
    Deodhar, Atul
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4178 - 4182
  • [10] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
    Deodhar, Atul
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth C.
    [J]. LANCET, 2018, 391 (10136): : 2213 - 2224
12345